• 1
    Wright A, Burden AC, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 3306.
  • 2
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 83753.
  • 3
    Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001; 30: 93582.
  • 4
    Stratton IM, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 32: 40512.
  • 5
    Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008; 31: 111.
  • 6
    Hirsch IB, Bergenstal RM, Parkin CG et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 7886.
  • 7
    Brunton S. Insulin regimens for type 2 diabetes mellitus. J Fam Pract 2006; 55: 10S17S.
  • 8
    Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28: 156981.
  • 9
    Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 5866.
  • 10
    Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 8815.
  • 11
    Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007; 9: 6309.
  • 12
    Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 2605.
  • 13
    Malone JK, Kerr LE, Campaigne BN et al., for the Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomised, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 203444.
  • 14
    Kann P, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006; 114: 52732.
  • 15
    Wenying Y, Qiuhe J, Dalong Z et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008; 31: 8526.
  • 16
    Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin 2005; 21: 56570.
  • 17
    Ligthelm RJ, Borzì V, Gumprecht J et al. Importance of observational studies in clinical practice. Clin Ther 2007; 29: 128492.
  • 18
    Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008; 62: 10138.
  • 19
    Valensi P, Benroubi M, Borzi V et al., on behalf of the IMPROVE™ Study Group Expert Panel. The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008; 62: 180919.
  • 20
    Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006; 15: 48191.
  • 21
    Liebl A, Prager R, Binz K et al., PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomised controlled trial. Diabetes Obes Metab 2009; 11: 4552.
  • 22
    Barnett A, Begg A, Dyson P et al. Insulin for type 2 diabetes: choosing a second line insulin regimen. Int J Clin Pract 2008; 62: 164753.